Jost Klawitter
Concepts (407)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dronabinol | 24 | 2026 | 247 | 3.870 |
Why?
| | Cannabinoids | 16 | 2026 | 182 | 3.490 |
Why?
| | Tandem Mass Spectrometry | 18 | 2026 | 576 | 3.090 |
Why?
| | Cannabidiol | 15 | 2025 | 136 | 2.920 |
Why?
| | Endocannabinoids | 7 | 2026 | 57 | 2.750 |
Why?
| | Cannabis | 21 | 2026 | 509 | 2.230 |
Why?
| | Chromatography, High Pressure Liquid | 12 | 2024 | 594 | 2.040 |
Why?
| | Immunosuppressive Agents | 14 | 2019 | 846 | 1.760 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 7 | 2022 | 235 | 1.660 |
Why?
| | Kidney | 18 | 2022 | 1495 | 1.540 |
Why?
| | Metabolomics | 14 | 2025 | 727 | 1.410 |
Why?
| | Sirolimus | 8 | 2019 | 281 | 1.400 |
Why?
| | Mass Spectrometry | 8 | 2021 | 750 | 1.370 |
Why?
| | Chromatography, Liquid | 10 | 2026 | 454 | 1.350 |
Why?
| | Cyclosporine | 8 | 2019 | 265 | 1.300 |
Why?
| | Limit of Detection | 9 | 2024 | 97 | 1.210 |
Why?
| | Hallucinogens | 8 | 2024 | 108 | 1.150 |
Why?
| | Kidney Transplantation | 12 | 2025 | 704 | 0.930 |
Why?
| | Secologanin Tryptamine Alkaloids | 1 | 2024 | 4 | 0.880 |
Why?
| | Alkaloids | 1 | 2024 | 28 | 0.870 |
Why?
| | Oxylipins | 1 | 2025 | 47 | 0.870 |
Why?
| | Mitragyna | 1 | 2024 | 8 | 0.870 |
Why?
| | Diphosphonates | 1 | 2025 | 68 | 0.850 |
Why?
| | Proteomics | 11 | 2020 | 1195 | 0.840 |
Why?
| | Glycerides | 1 | 2024 | 17 | 0.820 |
Why?
| | Arachidonic Acids | 1 | 2024 | 43 | 0.810 |
Why?
| | Proteome | 3 | 2016 | 518 | 0.800 |
Why?
| | Deoxycytidine | 1 | 2025 | 221 | 0.790 |
Why?
| | Analgesia | 1 | 2024 | 105 | 0.760 |
Why?
| | Metabolome | 6 | 2025 | 384 | 0.650 |
Why?
| | Pain | 1 | 2025 | 779 | 0.610 |
Why?
| | Biomarkers | 14 | 2025 | 4271 | 0.600 |
Why?
| | Marijuana Smoking | 5 | 2025 | 250 | 0.600 |
Why?
| | Milk, Human | 1 | 2021 | 172 | 0.600 |
Why?
| | Inflammation | 5 | 2025 | 2878 | 0.600 |
Why?
| | Plant Extracts | 5 | 2024 | 187 | 0.590 |
Why?
| | Graft Rejection | 6 | 2018 | 540 | 0.570 |
Why?
| | Everolimus | 2 | 2015 | 111 | 0.520 |
Why?
| | Urine | 1 | 2017 | 62 | 0.520 |
Why?
| | Reproducibility of Results | 9 | 2024 | 3409 | 0.510 |
Why?
| | Isoprostanes | 3 | 2012 | 15 | 0.510 |
Why?
| | Glomerular Filtration Rate | 7 | 2022 | 760 | 0.500 |
Why?
| | Energy Metabolism | 8 | 2022 | 935 | 0.480 |
Why?
| | Arthritis, Rheumatoid | 1 | 2025 | 1169 | 0.480 |
Why?
| | Plasma | 1 | 2017 | 225 | 0.460 |
Why?
| | Humans | 66 | 2026 | 144759 | 0.460 |
Why?
| | Rats | 15 | 2026 | 5597 | 0.450 |
Why?
| | Mitochondria | 4 | 2017 | 984 | 0.430 |
Why?
| | Male | 51 | 2026 | 72315 | 0.430 |
Why?
| | Oxidative Stress | 10 | 2019 | 1339 | 0.430 |
Why?
| | Mycophenolic Acid | 2 | 2014 | 120 | 0.430 |
Why?
| | Medical Marijuana | 3 | 2021 | 123 | 0.430 |
Why?
| | Administration, Oral | 5 | 2026 | 847 | 0.420 |
Why?
| | Lovastatin | 2 | 2013 | 37 | 0.410 |
Why?
| | Multiprotein Complexes | 1 | 2015 | 172 | 0.410 |
Why?
| | TOR Serine-Threonine Kinases | 2 | 2015 | 449 | 0.400 |
Why?
| | Tacrolimus | 4 | 2025 | 196 | 0.400 |
Why?
| | Glucuronides | 2 | 2022 | 18 | 0.390 |
Why?
| | Prenatal Exposure Delayed Effects | 3 | 2025 | 675 | 0.390 |
Why?
| | S-Adenosylhomocysteine | 1 | 2013 | 24 | 0.390 |
Why?
| | S-Adenosylmethionine | 1 | 2013 | 59 | 0.380 |
Why?
| | Female | 44 | 2026 | 78271 | 0.370 |
Why?
| | Fatty Acids | 1 | 2014 | 450 | 0.340 |
Why?
| | Animals | 30 | 2026 | 38058 | 0.330 |
Why?
| | Artifacts | 1 | 2011 | 139 | 0.330 |
Why?
| | Neurons | 2 | 2019 | 1640 | 0.310 |
Why?
| | Flowers | 2 | 2021 | 70 | 0.310 |
Why?
| | Atmospheric Pressure | 2 | 2021 | 26 | 0.300 |
Why?
| | Proteinuria | 1 | 2010 | 102 | 0.300 |
Why?
| | Proto-Oncogene Proteins c-akt | 3 | 2017 | 436 | 0.300 |
Why?
| | Substance Abuse Detection | 3 | 2025 | 106 | 0.290 |
Why?
| | Adult | 23 | 2026 | 40449 | 0.290 |
Why?
| | Signal Transduction | 7 | 2017 | 5226 | 0.280 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 2 | 2019 | 179 | 0.280 |
Why?
| | Kidney Medulla | 1 | 2008 | 31 | 0.280 |
Why?
| | Kidney Tubules, Collecting | 1 | 2008 | 27 | 0.280 |
Why?
| | Enzymes | 1 | 2008 | 65 | 0.270 |
Why?
| | Cyclophilins | 2 | 2017 | 40 | 0.260 |
Why?
| | Blotting, Western | 7 | 2012 | 1187 | 0.250 |
Why?
| | Parkinson Disease | 2 | 2024 | 600 | 0.250 |
Why?
| | Attention | 3 | 2026 | 457 | 0.250 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 4 | 2012 | 110 | 0.250 |
Why?
| | Cell Proliferation | 4 | 2011 | 2496 | 0.250 |
Why?
| | Nucleotides | 1 | 2007 | 128 | 0.240 |
Why?
| | Transplant Recipients | 2 | 2018 | 180 | 0.240 |
Why?
| | Microsomes, Liver | 2 | 2019 | 85 | 0.240 |
Why?
| | Cannabinoid Receptor Agonists | 5 | 2024 | 45 | 0.240 |
Why?
| | Amitriptyline | 1 | 2025 | 24 | 0.230 |
Why?
| | Disease Progression | 3 | 2022 | 2847 | 0.230 |
Why?
| | Abdominal Neoplasms | 1 | 2025 | 47 | 0.230 |
Why?
| | Rats, Wistar | 5 | 2012 | 451 | 0.230 |
Why?
| | Caffeine | 1 | 2025 | 74 | 0.220 |
Why?
| | Eicosanoids | 1 | 2025 | 58 | 0.220 |
Why?
| | Epilepsy | 2 | 2020 | 376 | 0.220 |
Why?
| | Adaptation, Physiological | 2 | 2025 | 570 | 0.220 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2021 | 851 | 0.220 |
Why?
| | Allografts | 1 | 2025 | 150 | 0.220 |
Why?
| | Isomerism | 1 | 2024 | 57 | 0.210 |
Why?
| | Drug Monitoring | 1 | 2008 | 395 | 0.210 |
Why?
| | Monoacylglycerol Lipases | 1 | 2024 | 5 | 0.210 |
Why?
| | Gene Expression Profiling | 1 | 2011 | 1782 | 0.210 |
Why?
| | Receptor, Cannabinoid, CB2 | 1 | 2024 | 11 | 0.210 |
Why?
| | Isotopes | 1 | 2024 | 34 | 0.210 |
Why?
| | Glycerol | 1 | 2024 | 90 | 0.200 |
Why?
| | Middle Aged | 16 | 2026 | 35875 | 0.200 |
Why?
| | Central Nervous System Stimulants | 1 | 2025 | 185 | 0.200 |
Why?
| | Plant Leaves | 1 | 2024 | 137 | 0.200 |
Why?
| | Dogs | 1 | 2025 | 437 | 0.200 |
Why?
| | Polysomnography | 1 | 2024 | 235 | 0.190 |
Why?
| | Kidney Failure, Chronic | 2 | 2025 | 598 | 0.190 |
Why?
| | Cross-Over Studies | 4 | 2025 | 601 | 0.190 |
Why?
| | Magnetic Resonance Spectroscopy | 6 | 2012 | 630 | 0.190 |
Why?
| | Psychomotor Performance | 1 | 2025 | 328 | 0.190 |
Why?
| | Kidney Diseases | 2 | 2017 | 427 | 0.180 |
Why?
| | Double-Blind Method | 5 | 2025 | 2029 | 0.180 |
Why?
| | Equilibrative Nucleoside Transporter 1 | 2 | 2012 | 20 | 0.180 |
Why?
| | Kynurenine | 1 | 2022 | 114 | 0.170 |
Why?
| | Anti-Inflammatory Agents | 1 | 2025 | 474 | 0.170 |
Why?
| | Endotoxemia | 1 | 2022 | 87 | 0.170 |
Why?
| | TRPP Cation Channels | 1 | 2022 | 74 | 0.170 |
Why?
| | Young Adult | 12 | 2026 | 14105 | 0.170 |
Why?
| | Birth Weight | 1 | 2024 | 522 | 0.170 |
Why?
| | Prostaglandins | 2 | 2019 | 94 | 0.170 |
Why?
| | Marijuana Use | 2 | 2024 | 213 | 0.170 |
Why?
| | Substance Withdrawal Syndrome | 1 | 2023 | 186 | 0.170 |
Why?
| | Mice | 11 | 2025 | 18339 | 0.170 |
Why?
| | Least-Squares Analysis | 2 | 2011 | 76 | 0.170 |
Why?
| | Proof of Concept Study | 1 | 2021 | 85 | 0.170 |
Why?
| | Drug Interactions | 3 | 2025 | 398 | 0.170 |
Why?
| | Tryptophan | 1 | 2022 | 181 | 0.170 |
Why?
| | Liver Transplantation | 2 | 2018 | 823 | 0.170 |
Why?
| | Quality Control | 1 | 2021 | 163 | 0.160 |
Why?
| | Marijuana Abuse | 1 | 2023 | 211 | 0.160 |
Why?
| | Sensation Disorders | 1 | 2020 | 41 | 0.160 |
Why?
| | Analgesics, Opioid | 2 | 2025 | 1143 | 0.160 |
Why?
| | Cytokines | 2 | 2025 | 2061 | 0.150 |
Why?
| | Pravastatin | 2 | 2021 | 43 | 0.150 |
Why?
| | Postoperative Complications | 2 | 2025 | 2919 | 0.150 |
Why?
| | Volatilization | 1 | 2019 | 52 | 0.150 |
Why?
| | Molecular Structure | 2 | 2014 | 499 | 0.150 |
Why?
| | Aging | 2 | 2026 | 1966 | 0.150 |
Why?
| | Myocardium | 2 | 2017 | 939 | 0.150 |
Why?
| | Nebulizers and Vaporizers | 1 | 2019 | 62 | 0.150 |
Why?
| | Intralaminar Thalamic Nuclei | 1 | 2019 | 21 | 0.150 |
Why?
| | Isoflurane | 1 | 2019 | 41 | 0.150 |
Why?
| | Persian Gulf Syndrome | 1 | 2019 | 18 | 0.150 |
Why?
| | Leukotrienes | 1 | 2019 | 27 | 0.150 |
Why?
| | Biological Availability | 2 | 2019 | 142 | 0.150 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2015 | 439 | 0.140 |
Why?
| | Rats, Inbred Lew | 4 | 2012 | 103 | 0.140 |
Why?
| | Amino Acids | 2 | 2016 | 521 | 0.140 |
Why?
| | Adenosine | 4 | 2013 | 255 | 0.140 |
Why?
| | Graft Survival | 2 | 2018 | 526 | 0.140 |
Why?
| | Anticonvulsants | 1 | 2020 | 235 | 0.140 |
Why?
| | Calcium Channels, T-Type | 1 | 2019 | 105 | 0.140 |
Why?
| | Group IV Phospholipases A2 | 1 | 2017 | 46 | 0.130 |
Why?
| | Cognition | 2 | 2023 | 1266 | 0.130 |
Why?
| | Therapies, Investigational | 1 | 2017 | 18 | 0.130 |
Why?
| | Time Factors | 5 | 2022 | 7173 | 0.130 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2017 | 35 | 0.130 |
Why?
| | Focal Adhesion Kinase 1 | 1 | 2017 | 32 | 0.130 |
Why?
| | Sleep | 1 | 2024 | 901 | 0.130 |
Why?
| | Endothelium | 2 | 2014 | 119 | 0.130 |
Why?
| | Ureteral Obstruction | 1 | 2017 | 62 | 0.130 |
Why?
| | Sex Characteristics | 3 | 2023 | 790 | 0.130 |
Why?
| | Pilot Projects | 3 | 2023 | 1886 | 0.130 |
Why?
| | Piperazines | 2 | 2009 | 381 | 0.130 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 2 | 2010 | 346 | 0.120 |
Why?
| | Glycolysis | 4 | 2012 | 339 | 0.120 |
Why?
| | Ischemia | 2 | 2012 | 421 | 0.120 |
Why?
| | Bone Marrow | 1 | 2017 | 304 | 0.120 |
Why?
| | Anesthesia | 1 | 2019 | 258 | 0.120 |
Why?
| | Sepsis | 1 | 2022 | 640 | 0.120 |
Why?
| | Air Pollution | 1 | 2019 | 327 | 0.120 |
Why?
| | Pyrimidines | 2 | 2009 | 532 | 0.120 |
Why?
| | Prognosis | 4 | 2025 | 4282 | 0.110 |
Why?
| | Depression | 1 | 2025 | 1558 | 0.110 |
Why?
| | MAP Kinase Signaling System | 1 | 2017 | 310 | 0.110 |
Why?
| | Mechanistic Target of Rapamycin Complex 2 | 1 | 2015 | 63 | 0.110 |
Why?
| | Child | 8 | 2025 | 22633 | 0.110 |
Why?
| | Lipoproteins, VLDL | 1 | 2014 | 21 | 0.110 |
Why?
| | Protein Kinases | 3 | 2017 | 315 | 0.110 |
Why?
| | Mice, Knockout | 6 | 2019 | 3121 | 0.110 |
Why?
| | Cognitive Dysfunction | 1 | 2020 | 461 | 0.100 |
Why?
| | Stearoyl-CoA Desaturase | 1 | 2014 | 66 | 0.100 |
Why?
| | Drug Stability | 2 | 2011 | 164 | 0.100 |
Why?
| | Brain | 2 | 2025 | 2933 | 0.100 |
Why?
| | Prospective Studies | 6 | 2025 | 7990 | 0.100 |
Why?
| | Linoleic Acids, Conjugated | 1 | 2013 | 7 | 0.100 |
Why?
| | Mice, Inbred C57BL | 7 | 2022 | 5992 | 0.100 |
Why?
| | Substance-Related Disorders | 1 | 2023 | 1094 | 0.100 |
Why?
| | Aged | 5 | 2026 | 25913 | 0.100 |
Why?
| | Rats, Sprague-Dawley | 3 | 2026 | 2527 | 0.100 |
Why?
| | Phosphates | 3 | 2012 | 180 | 0.100 |
Why?
| | 5'-Nucleotidase | 1 | 2013 | 49 | 0.100 |
Why?
| | Receptor, Adenosine A2B | 1 | 2013 | 65 | 0.100 |
Why?
| | Area Under Curve | 2 | 2025 | 330 | 0.100 |
Why?
| | Regression Analysis | 2 | 2012 | 1003 | 0.100 |
Why?
| | Dinoprost | 3 | 2019 | 49 | 0.100 |
Why?
| | MAP Kinase Kinase Kinase 5 | 1 | 2012 | 6 | 0.090 |
Why?
| | Models, Animal | 2 | 2013 | 392 | 0.090 |
Why?
| | Tissue Distribution | 4 | 2019 | 327 | 0.090 |
Why?
| | Sodium Chloride, Dietary | 1 | 2012 | 31 | 0.090 |
Why?
| | Polycystic Kidney Diseases | 1 | 2013 | 71 | 0.090 |
Why?
| | Oncogene Proteins | 1 | 2012 | 61 | 0.090 |
Why?
| | Principal Component Analysis | 1 | 2012 | 197 | 0.090 |
Why?
| | Cytochrome P-450 Enzyme System | 2 | 2025 | 162 | 0.090 |
Why?
| | Nucleosides | 1 | 2011 | 25 | 0.090 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2012 | 266 | 0.090 |
Why?
| | Transplantation | 1 | 2011 | 33 | 0.090 |
Why?
| | Reference Values | 1 | 2013 | 797 | 0.090 |
Why?
| | Transplantation, Homologous | 2 | 2025 | 415 | 0.090 |
Why?
| | PTEN Phosphohydrolase | 1 | 2012 | 164 | 0.080 |
Why?
| | Myocardial Ischemia | 1 | 2012 | 285 | 0.080 |
Why?
| | Mutation | 1 | 2022 | 4089 | 0.080 |
Why?
| | Glucose | 3 | 2017 | 1047 | 0.080 |
Why?
| | Cell Cycle | 2 | 2011 | 596 | 0.080 |
Why?
| | Organ Size | 2 | 2025 | 463 | 0.080 |
Why?
| | Citric Acid Cycle | 1 | 2010 | 59 | 0.080 |
Why?
| | Cell Line, Tumor | 4 | 2011 | 3540 | 0.080 |
Why?
| | Diabetic Nephropathies | 1 | 2013 | 318 | 0.080 |
Why?
| | Estrogens | 1 | 2013 | 380 | 0.080 |
Why?
| | Case-Control Studies | 4 | 2021 | 3604 | 0.080 |
Why?
| | Drug Therapy, Combination | 1 | 2012 | 1047 | 0.080 |
Why?
| | Regional Blood Flow | 1 | 2012 | 514 | 0.080 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2012 | 459 | 0.070 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2026 | 2027 | 0.070 |
Why?
| | High-Throughput Screening Assays | 1 | 2011 | 175 | 0.070 |
Why?
| | Cardiomyopathy, Dilated | 1 | 2012 | 359 | 0.070 |
Why?
| | Phenotype | 3 | 2022 | 3162 | 0.070 |
Why?
| | Prostaglandins A | 1 | 2009 | 8 | 0.070 |
Why?
| | Urinalysis | 1 | 2009 | 80 | 0.070 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2009 | 127 | 0.070 |
Why?
| | Osmotic Pressure | 1 | 2008 | 39 | 0.070 |
Why?
| | Adolescent | 7 | 2025 | 22428 | 0.070 |
Why?
| | Saline Solution, Hypertonic | 1 | 2008 | 42 | 0.070 |
Why?
| | Antineoplastic Agents | 2 | 2009 | 2194 | 0.070 |
Why?
| | Calcineurin Inhibitors | 1 | 2008 | 69 | 0.070 |
Why?
| | Disease Models, Animal | 2 | 2022 | 4557 | 0.070 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2008 | 157 | 0.070 |
Why?
| | Breast Neoplasms | 2 | 2011 | 2452 | 0.070 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 2115 | 0.060 |
Why?
| | Child, Preschool | 4 | 2025 | 11787 | 0.060 |
Why?
| | Pregnancy | 3 | 2025 | 7190 | 0.060 |
Why?
| | Cell Survival | 1 | 2010 | 1098 | 0.060 |
Why?
| | Myocytes, Cardiac | 1 | 2011 | 556 | 0.060 |
Why?
| | Diet | 1 | 2014 | 1273 | 0.060 |
Why?
| | Cell Line | 2 | 2012 | 2882 | 0.060 |
Why?
| | Organ Preservation Solutions | 1 | 2006 | 47 | 0.060 |
Why?
| | Hydroxylation | 2 | 2019 | 49 | 0.060 |
Why?
| | Nortriptyline | 1 | 2025 | 9 | 0.060 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 983 | 0.060 |
Why?
| | Tramadol | 1 | 2025 | 17 | 0.060 |
Why?
| | Lipoxygenase | 1 | 2025 | 15 | 0.060 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 1 | 2025 | 74 | 0.060 |
Why?
| | Organ Preservation | 1 | 2006 | 130 | 0.060 |
Why?
| | Longitudinal Studies | 1 | 2013 | 2947 | 0.060 |
Why?
| | Hair | 1 | 2025 | 88 | 0.060 |
Why?
| | Healthy Volunteers | 1 | 2025 | 215 | 0.060 |
Why?
| | Asthma | 1 | 2016 | 1767 | 0.050 |
Why?
| | Polymers | 1 | 2008 | 499 | 0.050 |
Why?
| | Creatinine | 2 | 2022 | 506 | 0.050 |
Why?
| | Amygdala | 1 | 2025 | 198 | 0.050 |
Why?
| | Acute Kidney Injury | 1 | 2012 | 865 | 0.050 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2009 | 881 | 0.050 |
Why?
| | Stroke | 1 | 2013 | 1256 | 0.050 |
Why?
| | Saliva | 1 | 2025 | 249 | 0.050 |
Why?
| | Memory, Short-Term | 1 | 2026 | 271 | 0.050 |
Why?
| | Infant, Newborn | 2 | 2025 | 6429 | 0.050 |
Why?
| | Follow-Up Studies | 2 | 2025 | 5408 | 0.050 |
Why?
| | TRPV Cation Channels | 1 | 2022 | 43 | 0.040 |
Why?
| | Reperfusion Injury | 1 | 2005 | 300 | 0.040 |
Why?
| | Protein Kinase Inhibitors | 1 | 2008 | 969 | 0.040 |
Why?
| | Mice, Mutant Strains | 1 | 2022 | 299 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2024 | 5868 | 0.040 |
Why?
| | Motivation | 1 | 2026 | 610 | 0.040 |
Why?
| | Harm Reduction | 1 | 2021 | 51 | 0.040 |
Why?
| | Self Report | 1 | 2025 | 872 | 0.040 |
Why?
| | Treatment Outcome | 3 | 2024 | 11679 | 0.040 |
Why?
| | Breast Feeding | 1 | 2024 | 448 | 0.040 |
Why?
| | Infant | 2 | 2025 | 10034 | 0.040 |
Why?
| | Databases, Genetic | 1 | 2022 | 248 | 0.040 |
Why?
| | Massachusetts | 1 | 2021 | 180 | 0.040 |
Why?
| | Interleukin-10 | 1 | 2022 | 309 | 0.040 |
Why?
| | Reward | 1 | 2022 | 247 | 0.040 |
Why?
| | Verbal Learning | 1 | 2020 | 73 | 0.040 |
Why?
| | 2-Propanol | 1 | 2019 | 20 | 0.040 |
Why?
| | Cytochrome P-450 CYP2C8 | 1 | 2019 | 14 | 0.040 |
Why?
| | Central Nervous System | 1 | 2022 | 281 | 0.040 |
Why?
| | Child Development | 1 | 2024 | 484 | 0.040 |
Why?
| | Dopamine | 1 | 2022 | 283 | 0.040 |
Why?
| | Imatinib Mesylate | 2 | 2009 | 77 | 0.040 |
Why?
| | Gulf War | 1 | 2019 | 15 | 0.040 |
Why?
| | Hippocampus | 1 | 2025 | 965 | 0.040 |
Why?
| | Calibration | 1 | 2019 | 151 | 0.040 |
Why?
| | Mice, 129 Strain | 1 | 2019 | 86 | 0.040 |
Why?
| | Metabolic Clearance Rate | 1 | 2019 | 114 | 0.040 |
Why?
| | Half-Life | 1 | 2019 | 151 | 0.040 |
Why?
| | Membrane Potentials | 1 | 2019 | 280 | 0.040 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2019 | 93 | 0.040 |
Why?
| | Lipopolysaccharides | 1 | 2022 | 863 | 0.040 |
Why?
| | Benzamides | 2 | 2009 | 224 | 0.040 |
Why?
| | Surface Properties | 1 | 2019 | 410 | 0.040 |
Why?
| | Metabolic Networks and Pathways | 1 | 2019 | 187 | 0.040 |
Why?
| | Gene Knockdown Techniques | 1 | 2019 | 336 | 0.030 |
Why?
| | Age Factors | 1 | 2026 | 3333 | 0.030 |
Why?
| | Analgesics | 1 | 2020 | 228 | 0.030 |
Why?
| | Protein Isoforms | 1 | 2019 | 402 | 0.030 |
Why?
| | Therapeutic Equivalency | 1 | 2017 | 31 | 0.030 |
Why?
| | Staphylococcus aureus | 1 | 2022 | 455 | 0.030 |
Why?
| | Bayes Theorem | 1 | 2020 | 433 | 0.030 |
Why?
| | Veterans Health | 1 | 2019 | 189 | 0.030 |
Why?
| | Postural Balance | 1 | 2020 | 240 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2017 | 138 | 0.030 |
Why?
| | Malates | 1 | 2016 | 7 | 0.030 |
Why?
| | Environmental Monitoring | 1 | 2019 | 377 | 0.030 |
Why?
| | Single-Blind Method | 1 | 2017 | 312 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2017 | 175 | 0.030 |
Why?
| | Betaine | 1 | 2016 | 65 | 0.030 |
Why?
| | DNA Damage | 1 | 2019 | 430 | 0.030 |
Why?
| | Body Mass Index | 1 | 2024 | 2438 | 0.030 |
Why?
| | 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid | 1 | 2015 | 5 | 0.030 |
Why?
| | Linoleic Acids | 1 | 2015 | 6 | 0.030 |
Why?
| | Hydroxyeicosatetraenoic Acids | 1 | 2015 | 35 | 0.030 |
Why?
| | Executive Function | 1 | 2020 | 461 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 2 | 2025 | 3863 | 0.030 |
Why?
| | Enzyme Activation | 1 | 2017 | 766 | 0.030 |
Why?
| | Lipids | 1 | 2020 | 710 | 0.030 |
Why?
| | Fibrosis | 1 | 2017 | 548 | 0.030 |
Why?
| | Retrospective Studies | 1 | 2013 | 17066 | 0.030 |
Why?
| | Rats, Inbred WF | 1 | 2014 | 8 | 0.030 |
Why?
| | DNA Methylation | 1 | 2019 | 681 | 0.030 |
Why?
| | Arachidonate 12-Lipoxygenase | 1 | 2013 | 17 | 0.030 |
Why?
| | Arachidonate 15-Lipoxygenase | 1 | 2013 | 20 | 0.030 |
Why?
| | Sex Factors | 1 | 2019 | 2112 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2022 | 2363 | 0.020 |
Why?
| | Drug Synergism | 1 | 2014 | 357 | 0.020 |
Why?
| | bcl-2-Associated X Protein | 1 | 2013 | 54 | 0.020 |
Why?
| | Infarction, Middle Cerebral Artery | 1 | 2013 | 41 | 0.020 |
Why?
| | Protein Deglycase DJ-1 | 1 | 2012 | 15 | 0.020 |
Why?
| | Smoking | 1 | 2020 | 1472 | 0.020 |
Why?
| | Ion Transport | 1 | 2012 | 63 | 0.020 |
Why?
| | Body Composition | 1 | 2016 | 706 | 0.020 |
Why?
| | Gluconeogenesis | 1 | 2012 | 83 | 0.020 |
Why?
| | Nucleoside Transport Proteins | 1 | 2012 | 8 | 0.020 |
Why?
| | No-Reflow Phenomenon | 1 | 2012 | 7 | 0.020 |
Why?
| | Dipyridamole | 1 | 2012 | 28 | 0.020 |
Why?
| | Receptors, Purinergic P1 | 1 | 2012 | 30 | 0.020 |
Why?
| | Chimerism | 1 | 2012 | 35 | 0.020 |
Why?
| | Incidence | 1 | 2018 | 2879 | 0.020 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2012 | 73 | 0.020 |
Why?
| | Inosine | 1 | 2011 | 14 | 0.020 |
Why?
| | Receptors, Purinergic | 1 | 2011 | 20 | 0.020 |
Why?
| | Neuroprotective Agents | 1 | 2013 | 143 | 0.020 |
Why?
| | Scutellaria | 1 | 2011 | 3 | 0.020 |
Why?
| | Scutellaria baicalensis | 1 | 2011 | 4 | 0.020 |
Why?
| | Overweight | 1 | 2016 | 609 | 0.020 |
Why?
| | Cytoskeleton | 1 | 2012 | 195 | 0.020 |
Why?
| | Solid Phase Extraction | 1 | 2011 | 25 | 0.020 |
Why?
| | Colorado | 1 | 2021 | 4564 | 0.020 |
Why?
| | Drug-Eluting Stents | 1 | 2011 | 88 | 0.020 |
Why?
| | Cyclic AMP | 1 | 2011 | 209 | 0.020 |
Why?
| | Methylation | 1 | 2011 | 242 | 0.020 |
Why?
| | Monitoring, Physiologic | 1 | 2012 | 289 | 0.020 |
Why?
| | Cell Hypoxia | 1 | 2011 | 247 | 0.020 |
Why?
| | Cohort Studies | 1 | 2021 | 5960 | 0.020 |
Why?
| | Gene Deletion | 1 | 2011 | 389 | 0.020 |
Why?
| | Needs Assessment | 1 | 2012 | 404 | 0.020 |
Why?
| | Nitric Oxide | 1 | 2014 | 897 | 0.020 |
Why?
| | K562 Cells | 1 | 2009 | 93 | 0.020 |
Why?
| | Cell Death | 1 | 2011 | 383 | 0.020 |
Why?
| | Reference Standards | 1 | 2009 | 177 | 0.020 |
Why?
| | Survival Analysis | 1 | 2012 | 1382 | 0.020 |
Why?
| | Phosphorylation | 1 | 2012 | 1732 | 0.020 |
Why?
| | Phospholipids | 1 | 2009 | 213 | 0.020 |
Why?
| | Lactic Acid | 1 | 2009 | 302 | 0.020 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2013 | 905 | 0.020 |
Why?
| | Lipid Metabolism | 1 | 2011 | 527 | 0.020 |
Why?
| | Raffinose | 1 | 2006 | 29 | 0.020 |
Why?
| | Procaine | 1 | 2006 | 10 | 0.020 |
Why?
| | F2-Isoprostanes | 1 | 2006 | 20 | 0.020 |
Why?
| | Potassium Chloride | 1 | 2006 | 40 | 0.020 |
Why?
| | Mannitol | 1 | 2006 | 40 | 0.020 |
Why?
| | In Situ Nick-End Labeling | 1 | 2006 | 121 | 0.020 |
Why?
| | Allopurinol | 1 | 2006 | 69 | 0.020 |
Why?
| | Creatine | 1 | 2006 | 63 | 0.010 |
Why?
| | Cold Ischemia | 1 | 2006 | 40 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2011 | 1985 | 0.010 |
Why?
| | Kidney Function Tests | 1 | 2006 | 157 | 0.010 |
Why?
| | Genotype | 1 | 2011 | 1833 | 0.010 |
Why?
| | Flow Cytometry | 1 | 2009 | 1173 | 0.010 |
Why?
| | Allantoin | 1 | 2005 | 2 | 0.010 |
Why?
| | Perfusion | 1 | 2006 | 250 | 0.010 |
Why?
| | Methylamines | 1 | 2005 | 40 | 0.010 |
Why?
| | Fatty Acids, Unsaturated | 1 | 2005 | 98 | 0.010 |
Why?
| | Glutathione | 1 | 2006 | 375 | 0.010 |
Why?
| | Risk Factors | 1 | 2018 | 10779 | 0.010 |
Why?
| | Uric Acid | 1 | 2005 | 166 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2011 | 4154 | 0.010 |
Why?
| | Mitochondria, Liver | 1 | 2003 | 70 | 0.010 |
Why?
| | Mitochondria, Heart | 1 | 2003 | 102 | 0.010 |
Why?
| | Organ Specificity | 1 | 2003 | 312 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2011 | 2608 | 0.010 |
Why?
| | Reactive Oxygen Species | 1 | 2005 | 621 | 0.010 |
Why?
| | United States | 1 | 2018 | 15966 | 0.010 |
Why?
| | Apoptosis | 1 | 2009 | 2430 | 0.010 |
Why?
| | Insulin | 1 | 2006 | 2507 | 0.010 |
Why?
|
|
Klawitter's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|